Search

C19H16Br4CuN2O2: monoclinic, P21/c (no. 14), a = 10.2649(3) Å, b = 10.1903(3) Å, c = 21.2494(6) Å, β = 100.522(1)°, V = 2185.36(11) Å3, Z = 4, wR 2 = 0.0730, T = 169.0 K.

C22H26Br2MnN5O4, monoclinic, P21/n (no. 14), a = 8.0106(4) Å, b = 14.5925(7) Å, c = 21.0425(11) Å, β = 100.330(2)°, V = 2419.9(2) Å3, Z = 4, Rgt(F) = 0.0372, wRref(F2) = 0.0766, T = 296.15 K.

C19H18Cl2CuN2O2, monoclinic, space group C2/c (no. 15), a = 21.010(3) Å, b = 11.3886(15) Å, c = 7.9578(10) Å, β = 100.725(4)°, V = 1870.8(4) Å3, Z = 4, wR 2 = 0.1620, T = 170.0 K.

C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V = 1344.80(9) Å3, Z = 4, Rgt(F) = 0.0239, wRref(F2) = 0.0611, T = 150(2) K.

C15H14Br2N2O3, triclinic, P1‾$P‾{1}$ (no. 2), a = 7.2748(3) Å, b = 9.0786(4) Å, c = 12.8613(5) Å, α = 99.458(2)°, β = 100.401(2)°, γ = 99.499(2)°, V = 807.35(6) Å3, Z = 2, Rgt(F) = 0.0253, wRref(F2) = 0.0673, T = 150.0 K.

C20H18Br2Cl2N2O2, monoclinic, P21/c (no. 14), a = 10.6105(8) Å, b = 17.1664(9) Å, c = 11.9848(9) Å, β = 97.682(3)°, V = 2163.4(3) Å3, Z = 4, Rgt(F) = 0.0330, wRref(F2) = 0.0823, T = 100(2) K.

C22H26Br2MnN5O4, monoclinic, P21/n (no. 14), a = 8.0106(4) Å, b = 14.5925(7) Å, c = 21.0425(11) Å, β = 100.330(2)°, V = 2419.9(2) Å3, Z = 4, Rgt(F) = 0.0372, wRref(F2) = 0.0766, T = 296.15 K. [ABSTRACT FROM AUTHOR]

Spinal cord injury (SCI) is a catastrophic event that can profoundly affect a patient's life, with far-reaching social and economic effects. A consequential sequence of SCI is the significant neurological or psychological deficit, which obviously contributes to the overall burden of this condition. To date, there is no effective treatment for SCI. Therefore, developing novel therapeutic strategies for SCI is highly prioritized. Flavonoids, one of the most numerous and ubiquitous groups of plant metabolites, are the active ingredients of traditional Chinese medicine such as Scutellaria baicalensis Georgi (Huang Qin) or Ginkgo biloba (Ying Xin). Accumulated research data show that flavonoids possess a range of key pharmacological properties such as anti-inflammatory, anti-oxidant, anti-tumor, anti-viral, anti-cardiovascular disease, immunomodulatory, and neuroprotective effects. Based on this, the flavonoids show therapeutic potential for SCI diseases. In this paper, we will review the pharmacological properties of different types of flavonoids for the treatment of SCI diseases, and potential underlying biochemical mechanisms of action will also be described. [ABSTRACT FROM AUTHOR]

C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V = 1344.80(9) Å3, Z = 4, Rgt(F) = 0.0239, wRref(F2) = 0.0611, T = 150(2) K. [ABSTRACT FROM AUTHOR]

C15H14Br2N2O3, triclinic, P1 (no. 2), a = 7.2748(3) Å, b = 9.0786(4) Å, c = 12.8613(5) Å, α = 99.458(2)°, β = 100.401(2)°, γ = 99.499(2)°, V = 807.35(6) Å3, Z = 2, Rgt(F) = 0.0253, wRref(F2) = 0.0673, T = 150.0 K. [ABSTRACT FROM AUTHOR]

C15H14Br2N2O3, triclinic, P1 (no. 2), a = 7.2748(3) Å, b = 9.0786(4) Å, c = 12.8613(5) Å, α = 99.458(2)°, β = 100.401(2)°, γ = 99.499(2)°, V = 807.35(6) Å3, Z = 2, Rgt(F) = 0.0253, wRref(F2) = 0.0673, T = 150.0 K. [ABSTRACT FROM AUTHOR]

C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V = 1344.80(9) Å3, Z = 4, Rgt(F) = 0.0239, wRref(F2) = 0.0611, T = 150(2) K. [ABSTRACT FROM AUTHOR]

Copyright of Zeitschrift für Kristallographie / New Crystal Structures is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

C20H18Br2Cl2N2O2, monoclinic, P21/c (no. 14), a = 10.6105(8) Å, b = 17.1664(9) Å, c = 11.9848(9) Å, β = 97.682(3)°, V = 2163.4(3) Å3, Z = 4, Rgt(F) = 0.0330, wRref(F2) = 0.0823, T = 100(2) K. [ABSTRACT FROM AUTHOR]

C19H16Br4CuN2O2: monoclinic, P21/c (no. 14), a = 10.2649(3) Å, b = 10.1903(3) Å, c = 21.2494(6) Å, β = 100.522(1)°, V = 2185.36(11) Å3, Z = 4, wR 2 = 0.0730, T = 169.0 K. [ABSTRACT FROM AUTHOR]